United States:
Humanigen Secures Exclusive Worldwide License For The Prevention Of GvHD Through GM-CSF Neutralization From The University Of Zurich
31 July 2019
Pearl Cohen Zedek Latzer Baratz
To print this article, all you need is to be registered or login on Mondaq.com.
Humanigen, Inc., (HGEN) (“Humanigen”) announced that
it has secured an exclusive worldwide license agreement from the
University of Zurich (UZH) for technology used to prevent GvHD
through GM-CSF neutralization. The technology was recently
featured in a publication in Science Translational Medicine
entitled “Graft-versus-host disease, but not
graft-versus-leukemia immunity, is mediated by GM-CSF-licensed
myeloid cells”1. The Humanigen license covers various patent
applications filed by UZH which complement and broaden
Humanigen’s leadership position in the application of GM-CSF
and expand Humanigen’s development platform to include
improving allogeneic HSCT.
https://www.proactiveinvestors.com/companies/stocktube/14161/humanigen-inks-licensing-agreement-with-the-university-of-zurich-to-strengthen-its-treatment-of-graft-versus-host-disease-in-leukemia-patients-14161.html
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Intellectual Property from United States
Are Your NDAs Up To Date?
Wolf, Greenfield & Sacks, P.C.
Nondisclosure agreements (NDAs) can be used to protect companies' confi dential and trade secret information. But you should resist the urge to have a vendor...
Legal Implications Of New York Times vs. OpenAI
BoyarMiller
The New York Times recently filed a landmark lawsuit against OpenAI and Microsoft, accusing them of copyright infringement in the training of the chatbot ChatGPT which launched just over a year ago.